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ttp://dx.doi.org/10.1016/j.ajpath.2014.05.012The forkhead box O (FOXO) family has been extensively investigated in aging and metabolism, but its
role in tissue-repair processes remains largely unknown. Herein, we clarify the molecular aspect of the
FOXO family in skin wound healing. We demonstrated that Foxo1 and Foxo3a were both up-regulated
during murine skin wound healing. Partial knockout of Foxo1 in Foxo1þ/ mice throughout the body led
to accelerated skin wound healing with enhanced keratinocyte migration, reduced granulation tissue
formation, and decreased collagen density, accompanied by an attenuated inﬂammatory response, but
we observed no wound phenotype in Foxo3a/ mice. Fibroblast growth factor 2, adiponectin, and
notch1 genes were signiﬁcantly increased at wound sites in Foxo1þ/ mice, along with markedly altered
extracellular signaleregulated kinase 1/2 and AKT phosphorylation. Similarly, transient knockdown of
Foxo1 at the wound site by local delivery of antisense oligodeoxynucleotides enhanced skin wound
healing. The link between FOXO1 and scarring extends to patients, in particular keloid scars, where we
see FOXO1 expression markedly increased in ﬁbroblasts and inﬂammatory cells within the otherwise
normal dermis. This occurs in the immediate vicinity of the keloid by comparison to the center of the
mature keloid, indicating that FOXO1 is associated with the overgrowth of this ﬁbrotic response into
adjacent normal skin. Overall, our data indicate that molecular targeting of FOXO1 may improve the
quality of healing and reduce pathological scarring. (Am J Pathol 2014, 184: 2465e2479; http://
dx.doi.org/10.1016/j.ajpath.2014.05.012)Supported in part by the Ministry of Education, Culture, Sports,
Science, and Technology of Japan Grants-in-Aid for Young Scientists
(A) 21689049 and 24689069, Challenging Exploratory Research
grants 23650484 and 25560055 (R.M.), Takeda Science Foundation
(R.M.), Uehara Memorial Foundation (R.M.), Nakatomi Foundation
(R.M.), The Wellcome Trust Senior Investigator Award 097791MA
(P.M.), and The Royal Society International Joint Project (R.M. and
P.M.).
Disclosures: None declared.The skin plays a major role in protecting us against all
extrinsic traumatic factors (ie, microbes, UV radiation,
heat, and chemicals). Damage to the skin immediately
triggers tissue repair mechanisms alongside a robust in-
ﬂammatory response for host defense.1 Skin wound heal-
ing is generally considered to consist of three phases:
inﬂammation, proliferation/migration, and maturation.
During an acute wound inﬂammatory response, manystigative Pathology.
.
Mori et alneutrophils rapidly migrate into damaged tissues to protect
against microbes, followed by macrophages that contribute
to formation of an associated granulation tissue, including
the wound angiogenic response. Unfortunately, this wound
inﬂammatory response also contributes to the ﬁnal ﬁbrotic
outcome of adult tissue repair.2 In parallel with connective
tissue repair, epithelial cells migrate over the newly
forming granulation tissue to cover the wound site in a
process known as re-epithelialization.3 Finally, the wound
tissues are partially remodeled, including some removal of
excess extracellular matrix at the scar site by proteolytic
degradation.4
Tissue repair speed and quality are dependent on aging
and metabolic status at a whole-body level, in addition to
local immunity and cellular responses at the wound site.5,6
The skin is one of the clearest indicators of aging, and skin
healing is highly associated with the aging process. Skin
repair occurs perfectly, without scarring, until fairly late in
gestation (embryonic 14 days in the mouse and the end of
the second trimester in humans).7 By contrast, elderly
persons are known to exhibit impaired healing. To date,
several studies have, therefore, focused on the molecular
mechanisms linking tissue repair and skin biological fea-
tures with age- and/or metabolic-related genes.8e12 A
worldwide increase in patients with delayed skin wound
healing due to an abnormal healing process is linked with
aging, diabetes, malnutrition, chemotherapy, and heredi-
tary diseases.
The mammalian forkhead box O (FOXO) is a family of
transcription factors consisting of FOXO1, FOXO3A,
FOXO4, and FOXO6. These proteins remain transcrip-
tionally active in the nucleus in the absence of environ-
mental and growth factors.13 Modiﬁcation of FOXO leads
to its translocation to the cytoplasm and/or its degradation,
resulting in the suppression of transcriptional activity.
Foxo1 deﬁciency (Foxo1/) in embryonic mice has been
shown to be lethal, causing abnormal vascular develop-
ment.14,15 We have previously reported that FOXO1 plays
a key role in aging and in caloric restriction and exhibits
antineoplastic characteristics.16 Several lines of evidence
suggest that FOXO proteins may play several key roles
during tissue repair. Sarcopenia is an age-associated
degenerative condition resulting in the loss of skeletal
muscle mass and muscle tissue repair.17 Activation of the
FOXO family is implicated in skeletal muscle regenera-
tion.18 In skin wounds, Foxo1 and Foxo4 are overly
expressed in the transcription factor binding sites of pro-
moters from many differentially expressed genes in the
epidermis.19 In diabetic mice, impaired skin wound healing
is associated with enhanced activation of FOXO1.20 Other
studies have recently reported that re-epithelialization
during scalp wound healing is impaired in keratinocyte-
speciﬁc Foxo1/ mice.21 However, the full involvement
of FOXO family members and their mechanism of action
in all cell lineages involved in skin wound healing and
scarring in vivo remains largely unknown.2466Herein, we investigated the molecular functions for
FOXO family gene members in skin wound healing, and
their potential application in a clinical setting. We ﬁnd
that heterozygous Foxo1-deﬁcient (Foxo1þ/) mice
exhibit accelerated skin wound healing, decreased scar-
ring, and enhanced keratinocyte migration. Acute
knockdown of the FOXO1 protein at wound sites [using
Foxo1 antisense oligodeoxynucleotides (AS ODNs)]
improved the quality of healing. We also suggest that
FOXO1 may be implicated in the development of human
keloids, because the altered expression of FOXO1 during
this process is race dependent. Our ﬁndings suggest that
modulating expression of FOXO1 may regulate wound
healing and scar formation and, thus, are potential
therapeutic targets for improving wound healing in the
clinic.
Materials and Methods
Wound Model
All experiments were conducted according to the Ethics
Review Committee for Animal Experimentation (numbers
1108010940-7 and 1311121101) at Nagasaki University
(Nagasaki, Japan). The generation of Foxo1þ/ and
Foxo3a/ mice has been described previously.16,22 The
wound model was performed as previously described.23 In
brief, four full-thickness excisional (4-mm biopsy punch;
Kai Industries, Tokyo, Japan) wounds or two full-
thickness incisional wounds (1 cm) in the dorsal skin
(after shaving under anesthesia) were performed in 7- to
12-week-old mice. Wounds were then harvested using a 6-
mm biopsy punch (Kai Industries) and recorded using a
digital camera. Areas were calculated using PhotoshopCS4
(Adobe Systems, San Jose, CA).
Human Samples
Human keloid tissue samples were harvested from Japanese
and African American patients at the time of surgery, and
diagnosis was conﬁrmed by routine pathological examina-
tion (Supplemental Table S1). Normal skin tissue samples
were harvested from the immediate vicinity of the keloid
site. All experiments were conducted with the approval of
the ethics committee of Nagasaki University Hospital
(number 09062523-2), and in accordance with the Decla-
ration of Helsinki principles. Written informed consent was
obtained from each individual.
Histological Features
Tissue was ﬁxed in 4% paraformaldehyde for parafﬁn
embedding. Sections (6 mm thick) were used for various
staining techniques: H&E, Masson’s trichrome, Pic-
rosirius red, and immunohistochemistry (IHC) for
FOXO1, neutrophils, F4/80, proliferating cell nuclearajp.amjpathol.org - The American Journal of Pathology
Foxo1 in Skin Wound Healing and Scarringantigen (PCNA), and phosphoeextracellular signale
regulated kinase (pERK). Observations were made
via microscopy [polarized light, epiﬂuorescence, or
confocal (C2þ system; Nikon Corp., Tokyo, Japan)].
Table 1 List of Antibodies
Primary antibody*
(manufacturer) Species Dilution Blocking (manufacturer)y
AKT (pan)
(CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
Life Science, Osaka, Jap
Phospho-AKT (pan)
(CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
CD31
(BD Pharmingen,
San Jose, CA)
Rat 1:200
(IHC-f)
Blocking One Histo (Nacal
Kyoto, Japan)
F4/80
(Abcam,
Cambridge, UK)
Rat 1:400
(IHC-p)
Blocking One Histo (Nacal
FOXO1
(Abcam)
Rabbit 1:400
(IHC-p)
Blocking One Histo (Nacal
FOXO1
(CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
Phospho-FOXO1
(Thr24) (CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
FOXO3A
(CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
Phospho-FOXO3A
(Ser318/321)
(CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
FOXO4
(CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
p44/42 MAPK
(ERK1/2)
(CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
Phospho-p44/42
MAPK (ERK1/2)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
(CST) 1:200
(ICC)
Blocking One Histo (Nacal
PCNA
(Abcam)
Mouse 1:400
(IHC-p and
IHC-f)
Blocking One Histo (Nacal
Myosin IIb
(CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
NF-kB p65
(CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
Phospho-NF-kB
p65 (Ser536)
(CST)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
Neutrophil
(Abcam)
Rat 1:400
(IHC-p)
Blocking One Histo (Nacal
a-Tubulin
(Abcam)
Rabbit 1:1000
(WB)
PVDF Blocking Reagent (TO
b-Actin
(Abcam)
Rabbit 1:5000
(WB)
PVDF Blocking Reagent (TO
*Overnight incubation of primary Abs at 4C (IHC-p, IHC-f, ICC, and WB).
yBlocking time: 2 hours at room temperature.
zIncubation of second Abs for 1 hour at room temperature.
CST, Cell Signaling Technology, Danvers, MA; f, frozen section; HRP, horseradis
The American Journal of Pathology - ajp.amjpathol.orgNIS-Elements C software version 4.13 or AR software
version 4.0 (Nikon Corp.) was used for data analysis.
Immunostaining procedures and antibody information are
listed in Table 1.Secondary antibody (manufacturer)z Dilution
YOBO
an)
a-Rabbit IgG HRP-linked whole antibody
(GE Healthcare Japan, Tokyo, Japan)
1:10,000
YOBO) a-Rabbit IgG HRP-linked whole antibody 1:10,000
ai Tesque, Goat a-rabbit IgG Alexa Fluor 568
(Molecular Probes; Life Technologies,
Carlsbad, CA)
1:400
ai Tesque) Goat a-rabbit IgG Alexa Fluor 568
(Molecular Probes)
1:800
ai Tesque) Goat a-rabbit IgG Alexa Fluor 488 or 568
(Molecular Probes)
Biotinylated a-rabbit IgG (Vector Lab,
Burlingame, CA)
1:800
1:200
YOBO) a-Rabbit IgG HRP-linked whole antibody 1:10,000
YOBO) a-Rabbit IgG HRP-linked whole antibody
(GE Healthcare)
1:10,000
YOBO) a-Rabbit IgG HRP-linked whole antibody
(GE Healthcare)
1:10,000
YOBO) a-Rabbit IgG HRP-linked whole antibody
(GE Healthcare)
1:10,000
YOBO) a-Rabbit IgG HRP-linked whole antibody
(GE Healthcare)
1:10,000
YOBO) a-Rabbit IgG HRP-linked whole antibody
(GE Healthcare)
1:10,000
YOBO) a-Rabbit IgG HRP-linked whole antibody
(GE Healthcare)
1:10,000
ai Tesque) Goat a-rabbit IgG Alexa Fluor 568
(Molecular Probes)
1:1000
ai Tesque) Histofine mouse stain kit
(Nichirei Biosciences Inc., Tokyo, Japan)
YOBO) a-Rabbit IgG HRP-linked whole antibody 1:10,000
YOBO) a-Rabbit IgG HRP-linked whole antibody
(GE Healthcare)
1:10,000
YOBO) a-Rabbit IgG HRP-linked whole antibody
(GE Healthcare)
1:10,000
ai Tesque) Goat a-rabbit IgG Alexa Fluor 488
(Molecular Probes)
1:800
YOBO) a-Rabbit IgG HRP-linked whole antibody
(GE Healthcare)
1:10,000
YOBO) a-Rabbit IgG HRP-linked Whole antibody
(GE Healthcare)
1:10,000
h peroxidase; p, parafﬁn section; WB, Western immunoblotting.
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Mori et alAnalysis of Epithelial Tongue and Area of Granulation
Tissue
Measurement of epithelial tongue and area of granulation
tissue were performed as previously described.23 In brief,
the epithelial tongue on H&E-stained wound sections and
areas of granulation tissue on Masson’s trichrome staining
sections were measured using NIS-Elements AR software.
Analysis of Angiogenesis
Wounded skin was ﬁxed in 4% paraformaldehyde for 16
hours, then exposed to 10%, 20%, and 30% sucrose (each
percentage for 16 hours), and frozen in Tissue-Tek O.C.T.
Compound (Sakura Finetek Japan, Tokyo, Japan). Sections
(50 mm) were permeabilized with histological blocking re-
agent (Blocking One Histo; Nacalai Tesque, Kyoto, Japan)
and 0.3% Triton X-100 for 2 hours. IHC for CD31,
including antibody information, is listed in Table 1. Eval-
uation of three-dimensional imaging for blood vessels and
vascular density were obtained by confocal microscopy,
NIS-Elements C software, and IMARIS software version
7.7.1 (BITPLANE, Zurich, Switzerland).
TEM and Morphological Analysis of Collagen
Transmission electron microscopy (TEM) and morpholog-
ical analysis of collagen were performed as previously
described.23,24
Measurement of Macrophages and FOXO1-Positive Cells
at Human Intact Skin and Keloid Sites
F4/80-positive cells (indicative of macrophages) and FOXO1-
positive cells in the wound bed (deﬁned as the area surrounded
by unwounded skin, fascia, regenerated epidermis, and
eschar), keloids, or intact skinwere counted from three random
ﬁelds (0.14 mm2).
RNA Isolation and Quantitative Polymerase Chain
Reaction
RNA isolation and quantitative PCR were performed as pre-
viously described.24 The gene-speciﬁc primers and probes for
quantitative PCR analysis were obtained from TaqMan gene
expression assays (Applied Biosystems, Foster City, CA) and
gene-speciﬁc primer sets (Takara Bio, Shiga, Japan).
Extraction of Nuclear Protein and Measurement of
FOXO1 Activity
Nuclear proteins were extracted by the Nuclear Extract kit
(Active Motif Japan, Tokyo), according to the manufac-
turer’s instructions. Harvested skin wound sites were ho-
mogenized using TissueLyzer II (Qiagen, Hilden, Germany).2468FOXO activity was measured with the TransAM FKHR
(FOXO1/4; Active Motif Japan), according to the manufac-
turer’s instructions. FOXO1 consensus oligonucleotide-treated
extracts were used as the negative control. Absorbancewas read
by the spectrophotometer (model LS-PLATEmanager 2004;
Wako Pure Chemical Industries, Osaka, Japan). The degree of
FOXO1 binding activity was calculated as follows:
FOXO1 binding activity ðarbitrary unitsÞZ
optical density=mg of nuclear protein:
Total Protein Extraction and Western Immunoblot
Analysis
Harvested skin wound sites were homogenized using Tis-
sueLyzer II (Qiagen) and were added to T-PER Reagent
(Thermo Fisher Scientiﬁc, Waltham, MA), consisting of
proteinase and dephosphorylation inhibitor (Thermo Fisher
Scientiﬁc). Supernatant debris was eliminated using an
Ultrafree-MC 0.45-mm ﬁlter (Millipore, Bedford, MA).
Filtered protein samples were separated on a 4% to 12%
NuPAGE Novex Bis-Tris gel (Life Technologies, Carlsbad,
CA), transferred to polyvinylidene diﬂuoride (PVDF), and
blotted according to standard protocols (antibody details are
listed in Table 1). Protein bands were visualized by chem-
iluminescence (Thermo Fisher Scientiﬁc), and band in-
tensity was calculated using ImageJ software version 1.47a
(NIH, Bethesda, MD).
Cell Culture, Foxo1 siRNA Treatment, Wound Scratch
Assay, and Measurement of pERK Activity
Mouse primary keratinocytes (PKs; Cell Lines Service,
Eppelheim, Germany) were transfected with 100 nmol/L
Stealth RNAi Negative Control Medium GC Duplex 2 or
Stealth Foxo1 siRNA (Life Technologies) using the Neon
Transfection System (1400 V, 20 ms, two pulses) (Life
Technologies). The wound scratched assay was performed as
previously described.25 Recombinant mouse ﬁbroblast growth
factor 2 (FGF2; Cell Signaling Technology, Danvers, MA)
(100 ng/mL) was used. The intensity of pERK ﬂuorescence
was measured by NIS-Elements AR software (Nikon Corp.).
LPS Challenge
Lipopolysaccharide (LPS) (from Escherichia coli serotype
O55, phenol extraction) was obtained from Wako Pure
Chemical Industries and was reconstituted in saline. Mice
(aged 8 to 12 weeks; weight, approximately 30 g) were i.p.
injected with 1.0 mg of LPS, and their survival was monitored.
ELISA
Extracted proteins were measured by the myeloperoxidase
(MPO) mouse ELISA kit (Abcam, Cambridge, UK), ac-
cording to the manufacturer’s instructions.ajp.amjpathol.org - The American Journal of Pathology
Foxo1 in Skin Wound Healing and ScarringMicroarray Analysis
Cyanine 3elabeled complementary RNA was generated
from 200 ng of total RNA using the Low Input Quick Amp
Labeling Kit, one color (Agilent Technologies, Santa Clara,
CA), and was puriﬁed by the RNeasy mini kit (Qiagen),
according to the manufacturer’s instructions. Fragmented
cyanine 3elabeled complementary RNA (600 ng) was hy-
bridized to SurePrint G3 mouse GE microarray, 8  60 K
(Agilent Technologies), at 65C for 17 hours. The micro-
array was then washed and scanned using the DNA
microarray scanner (Agilent Technologies).
Analysis of microarray data was performed using Ingenuity
iReport (Ingenuity System, Redwood City, CA). Probe set
intensities were summarized and normalized using robust
multi-array average. Signiﬁcant differential expression was
determined by a moderated t-test (Limma) using a P value
cutoff of 0.05 and a fold-change cutoff of 1.5. All raw data are
available in the Gene Expression Omnibus database (http://
www.ncbi.nlm.nih.gov/geo; accession number GSE48473).
Screening AS ODN Candidates for Knockdown Studies
ASODNs and the in vitroASODN cleavage experiments were
both designed as previously described.23 Basic Local Align-
ment Search Tool (BLAST) searches for AS ODN sequences
(Table 2) were conducted to exclude any sequences that were
non-speciﬁc for Foxo1 mRNA using GenBank (http://www.
ncbi.nlm.nih.gov; accession number NM_019739). Foxo1
mRNA was transcribed from the Riken FANTOM FLS Clone
(clone E430027H20; DNAFORM, Kanagawa, Japan).
For in vivo experiments involving ODN delivery, ODNs
[1 or 10 mmol/L in 50 mL 30% Pluronic F-127 gel (Sigma-
Aldrich, St. Louis, MO), which acts as a slow-release
vehicle23] were topically applied immediately after
wounding (50 mL; 1 or 10 mmol/L of ODNs).
Statistical Analysis
All data are expressed as the means  SEM. Statistical
signiﬁcance was assessed by analysis of variance, followedTable 2 Sequences for Control and AS ODNs
Name Sequence
Control ODN 50-GTGTAACACGTCTATACG-30
Foxo1 AS (1273) 50-CTGGAGAGATGCTTTTTT-30
Foxo1 AS (1341) 50-GACCCAGGACTCGCAGGC-30
Foxo1 AS (1686) 50-GAATTTAGACTGGTGTTT-30
Foxo1 AS (1692) 50-CTGGGTGAATTTAGACTG-30
Foxo1 AS (1717) 50-GTATGTGTACTTTGAGTA-30
Foxo1 AS (1914) 50-AGGACCCGACTGTTGGGT-30
Foxo1 AS (1986) 50-ATTTTGTTATGAGATGCC-30
Foxo1 AS (2070) 50-TTCACCACATGGGGCAGG-30
Foxo1 AS (2095) 50-CATGGCAGATGTGTGAGG-30
Foxo1 AS (2138) 50-ACAGAGGCACTTGTAAAG-30
Foxo1 AS (2208) 50-ATCCTACCATAGCCATTG-30
The American Journal of Pathology - ajp.amjpathol.orgby: i) Tukey’s post hoc test for multiple comparisons, ii)
Dunnett’s post hoc test for comparisons of all columns
versus control, or iii) paired or unpaired Student’s t-test.
Survival curves were analyzed using Kaplan-Meier survival
analysis and were compared with the log-rank test. Statis-
tical analysis was performed using GraphPad Prism 5 soft-
ware (GraphPad Software, La Jolla, CA). Signiﬁcance was
reached at values of P < 0.05.
Results
Skin Wound Healing Accelerates in Foxo1þ/ Mice
We investigated the expression of Foxo in wild-type (WT)
mice after dorsal aseptic skin wounding by quantitative
PCR. Gene expression of Foxo1 was signiﬁcantly increased
3 and 7 days after injury and expression of Foxo3a was
signiﬁcantly increased 7 days after injury by comparison
with unwounded skin (Figure 1A). Gene expression of
Foxo4 was markedly low, and Foxo6 was not signiﬁcantly
induced. These results indicated that Foxo1 and Foxo3a
genes are the Foxo family members predominantly
expressed during the skin repair process.
We then explored the role of FOXO1 and FOXO3A in skin
wound healing in Foxo1þ/ and Foxo3a/ male mice,
respectively.Foxo1þ/malemice are viable despite expressing
<50% of both FOXO1 in intact skin (data not shown), and
Foxo1 mRNA in liver, spleen, muscle, adipose tissue, and
hippocampus.16 After 3 days of injury, Foxo1þ/ mice
exhibited a signiﬁcantly smaller wound area (57% 3.2%) by
comparison to time-matched WT mice (72%  4.0%)
(Figure 1, B and C). By contrast, wound closures in Foxo3a/
mice were not altered compared with WT mice (data not
shown). These results prompted us to further analyze the
function of FOXO1 in skin wound healing.
To determine which cells express FOXO1 protein during
skin wound healing, we performed IHC analysis. By only 1
day after injury, FOXO1 was markedly present in the leading
edge and basal layer of keratinocytes and hair follicles, and in
recruited neutrophils (Figure 1D and Supplemental
Figure S1). Seven days after injury, FOXO1 was present in
macrophages, ﬁbroblasts, and endothelial cells at the wound
site (Figure 1, E and F). Histological analysis allowed us to
quantify both the extent of re-epithelialization and the area of
granulation tissue at various time points during repair. The
length of epithelial wound tongues in Foxo1þ/ mice 3 days
after injury was markedly higher (813 94 mm) than for WT
mice (513  52 mm) (Figure 1, G and H). IHC for the pro-
liferation marker, PCNA, showed that the percentage of
proliferating cells in the epithelial tongue of Foxo1þ/mice 3
days after injury was markedly increased compared with WT
mice (55% versus 40%). Masson’s trichrome staining of
sections of excisional wounds revealed that the area of
granulation tissue in the midwound region of Foxo1þ/mice
was signiﬁcantly reduced (0.15  0.014 mm2) compared
with WT mice (0.26  0.021 mm2) (Figure 1, I and J).2469
Figure 1 Skinwound healing is accelerated in Foxo1þ/mice.A:Gene expressionofmurine Foxo family in skinwoundhealingmeasured by quantitative PCR relative
to 18S ribosomal RNA (nZ 4 to 6). B: Representative images for gross appearances of excisional wound in WT (white bars) and Foxo1þ/ (black bars) mice. C: The
proportion of the wound remaining open relative to the initial wound area at each time point (nZ 12).D: IHC for FOXO1 and neutrophils shows neutrophils, epithelium,
and hair follicle expressing FOXO1 1 day after injury in WT mice. Nuclei were counterstained with DAPI [wound margin (white arrowhead), leading edge of epithelia
(arrow), and FOXO1-expressing neutrophils (open arrowheads)]. IHC of FOXO1 and F4/80 or CD31 shows wound-inﬁltrated macrophages (E), ﬁbroblasts (open
arrowhead, E), and endothelial cells (F) at 7 days after injury in WT mice. G: H&E staining of re-epithelialization [wound margin (arrowheads) and the leading edge of
epithelia (arrows)]. Top panels: The higher-power ﬁeld of the bottom panels.H:Measurement of epithelial tongue at 3 days after injury (nZ 13). I:Middle of wound
tissue at 14 days after injury stainedwithMasson’s trichrome, and the extent (cross-sectional area) of granulation tissue visualized and quantiﬁed at themidpoint of the
wound (dotted lines) [woundmargin (arrowheads)]. J: Quantiﬁcation of the area of granulation tissue 14 days after injury (nZ 6). All values represent means SEM.
*P < 0.05, **P< 0.01, and ***P < 0.001. Scale bars: 100 mm (D and bottom panels in G); 10 mm (E and F); 500 mm (high-power ﬁelds in G and I).
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Foxo1 in Skin Wound Healing and ScarringBecause angiogenesis is crucial for granulation tissue for-
mation, and FOXO1 is known to be involved in vasculo-
genesis in embryonic and fetal development,14 we investigated
vessel outgrowth during the repair process in Foxo1þ/ versus
WT mice. The three-dimensional blood vessel network of the
wound was reconstructed via confocal microscopy of sections
stained for platelet endothelial cell adhesion molecule/CD31,
which is a marker for endothelial cells.26 These studies
revealed no difference in the vessel network in intact skin of
Foxo1þ/ and WTmice (0.033 0.0024 and 0.026 0.0057
mm3/mm3, respectively), and the same was true at both 7- and
14-day wound sites (Supplemental Figure S2).
Our analyses suggest that attenuated expression of FOXO1
protein leads to accelerated repair and improved quality of
skin wound healing, owing to enhanced migration of kerati-
nocytes in the early stage of wound healing, followed by
decreased area of granulation tissue formation. However, this
is not because of differences in wound angiogenesis.
The Inﬂammatory Response Attenuates at Wound Sites
of Foxo1þ/ Mice
Several leukocyte lineages inﬁltrate wound sites at various
time points during the skin repair process.2 Our IHC staining
showed that wound-inﬁltrated neutrophils and macrophagesThe American Journal of Pathology - ajp.amjpathol.orgexpressed FOXO1 protein (Figure 1, D and E). Neutrophils,
revealed by either neutrophil IHC or measurement of MPO,
were reduced in Foxo1þ/ wounds versus WT controls
(Figure 2, A and B). F4/80 IHC for macrophages27 conﬁrms a
similar reduction (by 40%) in macrophage numbers at wound
sites of Foxo1þ/ mice (Figure 2, C and D).
Because NF-kB plays a pivotal role in the inﬂammatory
response,28 we performed Western immunoblot analysis and
showed that phosphorylation levels of NF-kB p65 (Ser536) at
wound sites ofFoxo1þ/mice3days after injuryweremarkedly
reduced (by 38%) compared withWTmice (Figure 2, E and F).
In addition, we found that Foxo1þ/ mice exhibited signiﬁcant
resistance to high-dose LPS-induced endotoxin shock that leads
to activation of NF-kB signaling via Toll-like receptor 4 in vivo
(Supplemental Figure S3).29 Collectively, these data suggest
that FOXO1 may regulate inﬂammatory cell recruitment to
wound sites, and the reduced FOXO1 in Foxo1þ/ mice
dampens down this inﬂammatory response.
Expression and Phosphorylation of the FOXO Family at
Wound Sites
Our ﬁndings provide clear evidence that Foxo1þ/ mice
exhibit accelerated skin wound healing and enhanced re-
epithelialization at the early stage of skin wound healing andFigure 2 Attenuation of neutrophil and
macrophage inﬁltration and inﬂammatory responses
at wound sites of Foxo1þ/ mice. A: IHC for neu-
trophils (red) showing the number of wound-
inﬁltrated neutrophils at wound sites 1 day after
injury, which is reduced in Foxo1þ/ mice compared
with WT mice (nuclei were counterstained with
DAPI). B: MPO concentration using ELISA reveals
that MPO levels at wound sites of Foxo1þ/ mice are
signiﬁcantly reduced compared with WT mice (nZ 8
per group). C: IHC for macrophages using F4/80 at
the middle area of wound sites 7 days after injury. D:
Quantiﬁcation of F4/80-positive macrophages at
wound sites of WT mice (nZ 6 per group for 3 days,
and nZ 5 per group for 7 days) and Foxo1þ/ mice
(nZ 6 per group for both 3 and 7 days). E: Western
immunoblot analysis of pNF-kB p65 and total NF-kB.
Full scans for Western immunoblots in Supplemental
Figure S5A. F: Densitometric analysis for pNF-kB
activity over total NF-kB (n Z 4 to 5). All values
represent means SEM. *P < 0.05. Scale barZ 10
mm (A and C). ND, not detected.
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Mori et ala diminished inﬂammatory response. We next performed a
comprehensive gene expression proﬁle at wound sites of
Foxo1þ/ andWTmice, after ﬁrst conﬁrming reduced FOXO1
DNA binding activity. ELISA studies indicate reduced binding
of FOXO1 in cells from wound sites of Foxo1þ/mice 3 and 7
days after injury (66%  13% and 56%  15%, respectively)
compared with WT mice (Figure 3A). Similar results were
found for both gene (Table 3) and protein (Figure 3B) expres-
sion levels of FOXO1.
In human ﬁbroblasts, FOXO1 and FOXO3A have been
shown to affect Foxo1 gene expression.41 Thus, we exam-
ined the protein expression and phosphorylation levels of
FOXO1, FOXO3A, and FOXO4 at wound sites 3 days after
injury of Foxo1þ/ mice (Figure 3B). We ﬁnd that FOXO1
protein expression and its phosphorylation [pFOXO1
(Thr24)] level at wound sites were markedly decreased in
Foxo1þ/ mice, but expression levels of FOXO3A,2472pFOXO3A (Ser318/321), and FOXO4 were not altered in
either group. These results, and the pattern of expression of
Foxo family genes during skin repair (Figure 1A). indicate
that FOXOs at the wound site are predominantly regulated
by pFOXO1 (Thr24) and pFOXO3A (Ser318/321) in the
early stage of skin wound healing.
Activation of ERK1/2 Is Enhanced in Wound Sites of
Foxo1þ/ Mice
To determine the molecular mechanisms underlying
enhanced skin wound healing when FOXO1 protein
expression was reduced, we performed microarray analysis
on 3-day skin wound samples from Foxo1þ/ versus WT
mice. By using a fold-change cutoff of 1.5 (with a P value
cutoff of 0.05), we identiﬁed 387 and 269 differentially
regulated genes that are up- and down-regulated in Foxo1þ/Figure 3 ERK1/2 activation and myosin IIb
expression are enhanced at wound sites of Foxo1þ/
mice.A: FOXO1 binding activity in the nuclear wound
tissue extract was measured by immobilized oligo-
nucleotide ELISA. FOXO1 consensus oligonucleotide-
treated extracts were used as negative control
(n Z 2 to 4). B: Western immunoblot analysis of
wound tissue at 3 days shows weak expression of
total FOXO1 and pFOXO1 (Thr24) at wound sites of
Foxo1þ/ mice. Bands for total FOXO3A, pFOXO3A
(Ser318/321), and FOXO4 remain unchanged in both
groups. Full scans for Western immunoblot analysis
in Supplemental Figure S5B. C: Western immunoblot
analysis of pERK1/2 (Thr202/Tyr204), total ERK1/2,
pAKT (Ser473), total AKT, and myosin IIb. Full scans
for Western immunoblots in Supplemental
Figure S5C. D: Densitometric analysis of pERK1/2
(Thr202/Tyr204) and pAKT (Ser473) over total ERK1/
2 and AKT, respectively, andmyosin IIb (nZ 4 to 5).
E: Wound scratch assay 24 hours after treatment of
mFGF2 in PKs with control (left panel) or Foxo1
(right panel) siRNAs. F: Wound closure ratio
(n Z 4). G: Confocal images of pERK in mFGF2-
treated control PKs (left panel) and Foxo1 siRNA-
treated PKs (right panel) 24 hours after scratching
(nZ 3). H: Fluorescence intensity of pERK by mFGF2
24 hours after scratching in control PKs and Foxo1
siRNA-treated PKs (n Z 3). All values represent
means SEM. *P< 0.05. Scale bars: 100 mm (E); 50
mm (G).
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Table 3 Expression of Skin Wound-Related Genes
Gene symbol: name Ratio Molecular function Reference
Il24: interleukin 24 2.478 Cytokine 30
Ifna1/Ifna13: interferon, a 1 2.199 Cytokine 31
Itga1: integrin, a 1 2.316 Receptor 32
Notch1 1.944 Receptor 33
Adipoq: adiponectin, C1Q, and collagen domain containing 1.824 Cytokine 8,9
Npy2r: neuropeptide Y receptor Y2 1.821 Receptor 34
Lif: leukemia inhibitory factor 1.777 Cytokine 35
Fgf2: ﬁbroblast growth factor 2 (basic) 1.647 Growth factor 36e38
Myh10: myosin, heavy chain 10, nonmuscle 1.641 Actin-based motor protein 39
Adora1: adenosine A1 receptor 1.637 Receptor 40
Foxo1: forkhead box O1 1.92 Transcription factor
Gene expressions from the microarray data set (Supplemental Table S2). Compared with WT mice, a ratio >1.5 in Foxo1þ/ mice indicates a signiﬁcant
up-regulation (n Z 3 per group). Il24 may be a negative regulator of skin wound healing. Expression of Foxo1 serves as a positive control.
Foxo1 in Skin Wound Healing and Scarringmice, respectively (Supplemental Table S2). We next
screened for those molecules/pathways that might be most
likely to be promoting healing in Foxo1þ/ mice by
analyzing the molecular interactions between differentially
regulated genes, such as gene expression, activation, post-
translational modiﬁcation, and physical interactions
(Supplemental Table S3). Previous in vivo studies have
revealed skin wound healingerelated genes: Fgf2,36e38
adiponectin (Adipoq),8,9 and Notch1.33 Our results showed
that Fgf2, Adipoq, and Notch1 were signiﬁcantly (P < 0.05)
increased by 1.65-, 1.82-, and 1.94-fold, respectively, in
3-day wound sites of Foxo1þ/ mice (Table 3).
Two key signaling pathways may contribute to the
FOXO1 phenotype we observe. The ERK1/2 signaling
pathway is involved in cell migration and proliferation,25 and
the AKT signaling pathway is associated with skin wound
healing functions upstream of FOXO1.42 The ERK1/2 and
AKT pathways are activated by FGF2 and ADIPOQ,
contributing to epithelial and ﬁbroblast cell proliferation.8,43
Therefore, we investigated whether activation of ERK and
AKT pathways in wound sites of Foxo1þ/mice was altered.
The phosphorylation levels of ERK1/2 (Thr202/Tyr204) in
wound sites of Foxo1þ/ mice 3 days after injury were
markedly increased compared with WT (1.5  0.13 and
1.0  0.11, respectively) (Figure 3C). In contrast, the phos-
phorylation levels of AKT (Ser473) in wound sites of
Foxo1þ/ mice 7 days after injury were markedly decreased
compared with WT (0.56  0.054 and 1.0  0.20, respec-
tively) (Figure 3D).
Our microarray analysis showed that several cell
migratione and proliferation-related signals were signiﬁ-
cantly up-regulated, including myosin heavy chain 10
(Myh10) (1.64-fold). MYH10 generates the nonmuscle
myosin IIb isoform,44 which is downstream of the ERK1/2
pathway.45 Myosin IIb is expressed in both epidermis and
wound ﬁbroblasts,46 and Myh10 is markedly induced at
wound sites, in Foxo1þ/ mice (Table 3) in the current
study. We also see that protein levels of the myosin IIb
isoform are markedly increased in wound sites of Foxo1þ/
mice compared with WT (1.5  0.21 and 1.0  0.067,The American Journal of Pathology - ajp.amjpathol.orgrespectively) (Figure 3, C and D). Collectively, these results
suggest that expression of myosin IIb may be enhanced via
the ERK pathway at an early stage of wound repair in
Foxo1þ/ mice.
We next tested whether FOXO1 was involved in wound
FGF2 signaling, which contributes to the enhancement of cell
proliferation and migration in PKs. The in vitro wound
scratch assay demonstrated that wound closure in Foxo1
siRNA-treated PKs was not altered compared with control
PKs (1.23 0.15 and 1.0 0.04, respectively). Interestingly,
the migration of mouse FGF2 (mFGF2)etreated Foxo1
siRNA-treated PKs was signiﬁcantly enhanced from the
wound edge to the center of the wound (Figure 3, E and F).
Immunocytochemistry (ICC) was then used to investigate the
localization of pERK. In PKs exposed to mFGF2-treated
Foxo1 siRNA, pERK activation was mainly observed at
the wound edge rather than away from the wound site 24
hours after scratching. This response was signiﬁcantly higher
compared with control wounds (4.95 0.63 and 2.82 0.41,
respectively) (Figure 3, G and H). Taken together, these
ﬁndings indicate that FOXO1 may play a role in re-
epithelialization and migration of keratinocytes at wound
sites via the ERK and FGF2 pathways.
Collagen Organization Is Altered at Wound Sites of
Foxo1þ/ Mice
Scarring is the ﬁnal consequence of the wound healing pro-
cess, and is a measure of wound healing quality.1 To inves-
tigate whether altered FOXO1 expression inﬂuences the
development of scarring at wound sites, we monitored
scarring 21 days after making 1-cm incisional wounds to
Foxo1þ/ and WT mice (Figure 4A). Picrosirius red staining
showed type I collagen (red and yellow) and type III collagen
(green) bundle organization47 to be markedly reduced in
Foxo1þ/ mice 21 days after injury (Figure 4B).
To further analyze the development of a scar, we per-
formed TEM to reveal gross collagen bundling patterns,
individual collagen ﬁbril diameter, and the density of ﬁbrils
at the wound site. The morphological features of collagen2473
Mori et alwithin intact skin of Foxo1þ/ and WT mice were indis-
tinguishable (Supplemental Figure S4). Interestingly, the
ﬁbril diameter at the midregion wound sites of Foxo1þ/
mice was markedly (P < 0.001) reduced (61.5  0.49 nm)
compared with WT mice (63.3  0.46 nm) (Figure 4, C andFigure 4 Scarring at wound sites is attenuated in Foxo1þ/ mice. A: Gross ap
indicates wound edge). Images shown are representative of six independent experim
after injury for analysis of collagen ﬁbers and alignments [type I collagen (red and ye
tissue was visualized at the midpoint of the wound (dotted lines). Images shown a
taken as nonpolarized images. High-magniﬁcation details from boxed areas indic
croscopy. C: TEM images of connective tissue from midwound sites 21 days after in
this tissue. D: Histogram of total range of ﬁbril diameters in the wound site 21 days
three Foxo1þ/ mice). Fibril diameters at wound sites of Foxo1þ/ mice tend to be
wound sites at 21 days (nZ 3 to 4). F: Quantiﬁcation of gene expression of Col1a1
18S ribosomal RNA (n Z 8). All values represent means  SEM. *P < 0.05. Scale
2474D). Furthermore, intracollagen bundle spaces at wound sites
of Foxo1þ/ mice were signiﬁcantly (P < 0.05) increased
(0.62  0.094 mm2/mm2) compared with WT mice
(0.38  0.023 mm2/mm2) (Figure 4E), more closely resem-
bling those of unwounded skin. Gene expression of type Ipearance of scarring at the incisional wound 21 days after injury (asterisk
ents. B: Picrosirius redestained sections of incisional wound sites at 21 days
llow), type III collagen (green), and wound edge (arrowheads)]. Granulation
re representative of eight independent experiments. Low magniﬁcations were
ated are differential interference contract images using polarized light mi-
jury. High-magniﬁcation insets illustrate differing collagen ﬁbril diameters in
after injury (nZ 1090 ﬁbrils from three WT mice, and nZ 1354 ﬁbrils from
smaller than in WT mice. E: Quantiﬁcation of vacant extracellular spaces in
7 days after injury at wound sites (measured by quantitative PCR), relative to
bars: 50 mm (B); 1 mm (C); 100 nm (inset, C).
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Figure 5 Skin wound healing is accelerated in Foxo1 AS ODNetreated
wounds. A: Optimization of Foxo1 AS ODNs in vitro. Cleavage was visualized
when transcribed Foxo1 mRNA was incubated with control and AS ODNs
in vitro (n Z 2 independent experiments) (M1 and M2 Z RNA loading
markers). Sequences are shown in Table 2. Foxo1 AS ODN (1717) is more
efﬁcient than other Foxo1 AS ODNs. B: Western immunoblot analysis from
wound sites (6 hours after injury) to detect the effective dose of Foxo1 AS
ODN (1717) to decrease FOXO1 protein expression in wounds in vivo. Full
scans for Western immunoblots in Supplemental Figure S5D. C: Quantiﬁ-
cation of FOXO1 protein expression in wound sites exposed to 10 mmol/L
Foxo1 AS ODN (1717) (nZ 6 per group) reveals that FOXO1 is signiﬁcantly
reduced. Data are presented as the means  SEM and analyzed by Tukey’s
multiple-comparison tests. D: Representative photomicrographs for gross
appearances of excisional control and Foxo1 AS ODNetreated wounds at
various time points after wounding (n Z 12). E: The proportion of the
wound remaining open relative to the initial wound area at each time point
after the injury in control versus Foxo1 AS ODNetreated wounds (n Z 12
per group). All values represent means  SEM. *P < 0.05, **P < 0.01.
Foxo1 in Skin Wound Healing and Scarringcollagen a1 (Col1a1) was signiﬁcantly decreased at wound
sites of Foxo1þ/ mice 7 days after injury compared with WT
mice (0.58  0.073 and 0.82  0.063, respectively)
(Figure 4F). We suggest that these differences of collagen
assembly at wound sites play a key role in reducing scar
formation during the maturation phase of healing in Foxo1þ/
mice.
Acute Knockdown of FOXO1 Using AS ODNs Improves
Skin Wound Healing
Our Foxo1þ/ mouse data provide experimental evidence
that attenuation of FOXO1 expression may improve skin
wound healing. To further address our hypothesis and test
whether reducing levels of this transcription factor during the
repair process is a potential therapeutic strategy for
improving healing, we designed and optimized Foxo1-
speciﬁc AS ODNs in vitro (Figure 5A). We applied Foxo1
AS ODN (1717) (10 mmol/L in 30% Pluronic gel for 6 hours
at the wound site23) versus control ODN (with sequence
predicted to be nonbinding to other mRNAs) to 4-mm-
diameter adult skin wound sites (Figure 5, B and C).
Macroscopic analysis indicated that wound closure in Foxo1
AS ODNetreated wound sites 3 days after injury was
markedly accelerated (67%  2.4%) at early time points
during the repair process, compared with the control ODN-
treated wound (76%  3.0%) (Figure 5, D and E). Next,
we made a 1-cm incisional wound in the dorsal skin and
analyzed scarring (via TEM) with a 21-day treatment of
control ODN or Foxo1 AS ODN at the wound sites. The ﬁbril
diameter at the midregion was not altered (66.6  0.65 nm,
n Z 1336 from three mice) at Foxo1 AS ODNetreated
wound sites compared with control ODN-treated wound sites
(65.1  0.55 nm, n Z 1534 from three mice). Vacant
extracellular space at Foxo1 AS ODNetreated wound sites
was not altered (0.55  0.038 mm2/mm2, n Z 3) compared
with control ODN-treatedwound sites (0.44 0.038mm2/mm2,
nZ 3). These results indicated that acute down-regulation of
FOXO1 protein at the wound site using Foxo1 AS ODN
accelerated skin wound healing, but did not signiﬁcantly alter
scar quality.
Increased FOXO1 Is Associated with Human Keloid
Scars
Because of the altered level of scarring in our whole body
Foxo1þ/ mouse studies, we next chose to investigate
whether the expression pattern of FOXO1 was altered in
human keloid scars, which are an extreme instance of human
skin ﬁbrotic disease, typiﬁed by a hypertrophic epidermis,
and overgrowth of granulation tissue, which expands in a
claw-like way to invade adjacent normal skin.48,49 IHC
showed that FOXO1 was prominently present in suprabasal
keratinocytes of the hypertrophic epidermal layer of keloids
(Figure 6A), in addition to some ﬁbroblasts and inﬂammatory
cells (Figure 6B). Although FOXO1 in ﬁbroblasts was notThe American Journal of Pathology - ajp.amjpathol.orgstrongly expressed at deep keloid tissue sites (Figure 6C), it
was notably present in numerous ﬁbroblasts and inﬂamma-
tory cells in the immediate vicinity of keloid sites of the
normal dermal layer (Figure 6, D, E, and G). These results2475
Figure 6 Expression of FOXO1 at human keloids. AeC: IHC for FOXO1 shows that FOXO1 (brown) is highly present in basal lamina keratinocytes at
keloid sites in the Japanese population [nuclei are stained with hematoxylin (violet)] [FOXO1-expressing cells (arrowheads)]. D and E: FOXO1 is present
in normal epidermis and dermis in the immediate vicinity of keloid sites compared with mature keloid sites. F: IHC for FOXO1 shows highly prominent
FOXO1-positive cells at the surface and deep in keloid sites of African Americans compared with Japanese [mature deep keloid sites are shown (inset)].
Micrographs are representative of three and six sections for DeF and AeC, respectively. G: Percentage of FOXO1-positive cells at the intact skin in the
immediate vicinity of keloid sites (three cases) and in keloid sites (six cases). H: Percentage of FOXO1-positive cells at mature keloid sites of an African
American (three cases) and two Japanese (six cases) patients. I: A proposed model of the exacerbation of keloids by FOXO1. Elevated expression of
FOXO1 at the epidermis may cause hyperplasia of keloids. In contrast, numbers of FOXO1-expressing cells at deeply mature keloid sites are markedly
reduced. Intact skin in the vicinity of keloids appears normal. However, expression of FOXO1 is markedly increased compared with mature keloid,
suggesting that FOXO1-positive cells are associated with keloid expansion. Collectively, many FOXO1-expressing cells produce collagen and enhance the
inﬂammatory response, leading to the exacerbation of keloid scarring. All values represent means  SEM. *P < 0.05. Scale bars: 500 mm (A and D); 100
mm (B, C, E, and F).
Mori et alsuggested that FOXO1 was involved in expanding the
growth of keloid into adjacent normal skin sites and might be
driving the production of excessive extracellular matrix
protein.
The development of a keloid is known to be associated
with age, physiological conditions, and genetic back-
grounds. Keloids occur most frequently in individuals of2476African American descent.50 Therefore, we next performed
a comparative case report of keloids between African
American and Japanese to investigate the expression of
FOXO1. Levels of expression of FOXO1 in keratinocytes,
ﬁbroblasts, and inﬂammatory cells in all keloid sites were
markedly higher in African Americans compared with
Japanese (Figure 6, F and H). Collectively, these resultsajp.amjpathol.org - The American Journal of Pathology
Foxo1 in Skin Wound Healing and Scarringindicate that the development of skin ﬁbrotic diseases may,
in part, be regulated by FOXO1 (Figure 6I).Discussion
In the present study, we report accelerated and improved
eventual quality of skin wound healing in Foxo1þ/ mice,
because of enhanced re-epithelialization and a reduced in-
ﬂammatory response at sites of tissue damage. Foxo1 AS
ODNetreated wounds also exhibit improved skin wound
healing. Abnormal and diverse expression of FOXO1 is also
associated with the development of keloids in human pa-
tients. The present data provide a novel molecular insight
into the function of FOXO1 in skin wound healing and
suggest its potential as an anti-scarring therapeutic target.
Skin wounding initially leads to clot formation and a sig-
niﬁcant recruitment of neutrophils, which protect the tissue
breach by killing microbes and also release proinﬂammatory
cytokines, some of which act to draw in macrophages to the
wound. Thereafter, macrophages inﬁltrate the wound site and
secrete cytokines, chemokines, and growth factors, according
to the extent of tissue damage and infection state, thus
reﬂecting the degree of the inﬂammatory phase.1 The FOXO
family has been previously shown to regulate the homeo-
stasis of the immune system and the inﬂammatory
response.51 Conditional Foxo1/ mice exhibit an altered
phenotype, including T-cell homeostasis and tolerance.52e54
FOXO1 may play a role during the infection recognition and
clearance process55 because it is known that the bacterial
product, N-formylmethionyl-leucyl-phenylalanine, triggers
neutrophils to up-regulate myeloid leukemia cell differentia-
tion protein MCL1, which can form a complex with FOXO1.
Moreover, chromatin immunoprecipitation sequencing anal-
ysis using next-generation sequencing has revealed that
FOXO1 signiﬁcantly enhances Toll-like receptor 4 signaling
in macrophages.56 Activation of NF-kB affects the AKT-
FOXO1 signaling pathway.57 In the present study, the inﬁl-
tration of neutrophils and macrophages into wound sites and
the phosphorylation of NF-kB and AKT were attenuated in
Foxo1þ/mice. Overall, the FOXO1-mediated inﬂammatory
response may link to leukocyte recruitment and activation in
the skin wound healing process.
Re-epithelialization, involving keratinocyte migration and
proliferation, commences soon after skin damage and is
regulated by various factors, including keratinocyte growth
factor and others released by inﬁltrating inﬂammatory cells,
and ﬁbroblasts.2,3 Previous studies suggest that the effect of
FOXO1 in guiding cell migration/proliferation may be cell
type speciﬁc. For example, knockdown of Foxo1 in platelet-
derived growth factoretreated ﬁbroblasts has been shown to
enhance proliferation, indicating that attenuation of the
expression of FOXO1 is sufﬁcient for the enhancement of cell
growth.41 In contrast, keratinocyte-speciﬁc Foxo1/ in mice
impairs scalp wound healing because of reduced expression
of transforming growth factor b1.21 In our current study,The American Journal of Pathology - ajp.amjpathol.orgenhancement of re-epithelialization in Foxo1þ/ mice accel-
erated skin wound healing, which corresponded with an in-
crease in the expression of Fgf2, Adipoq, Notch1, andMyo10
(Table 3). Each of these, in turn, is known to play key roles in
various aspects of the repair process: FGF2 is crucial for re-
epithelialization in skin wound healing,37 whereas genetic
and pharmacological inhibition of Notch1 in mice markedly
impairs skin wound healing.33 Calmodulin-like protein-
mediated expression of MYO10 contributes to keratinocyte
motility and migration in humans and mice.39 ADIPOQ
promotes keratinocyte proliferation and migration via the
ERK pathway in vivo.8,9 We are exploring the mechanism
underlying FOXO-mediated regulation of cell proliferation
and migration in the presence of FGF2 at wound sites.
As well as enhanced rate of wound repair, we observe
reduced scarring in Foxo1þ/ mice. Scarring appears at the
ﬁnal stage of the skin wound healing process, and the
phenotype of scarring is dependent on diverse factors,
including inﬂammation, delayed healing, physiological
condition, age, and race.6,50,58 The regulation of collagen
expression via FOXO1 may depend on the tissue and cell
type, and this may be a consequence of both direct and/or
indirect effects. Knockdown of Foxo1 in UV-irradiated
human dermal ﬁbroblasts was shown to signiﬁcantly
decrease the expression of Col1a1.59 In contrast, expression
of liver Col1a1 was increased in the bile duct ligation-
induced experimental liver ﬁbrosis model of Foxo1þ/,
resulting in liver ﬁbrosis.60 Collagen organization is
controlled by several enzymes and extracellular matrix
proteins,61 and is considerably altered by normal aging.62,63
Activation of AKT is one of the main signaling pathways
for type I procollagen synthesis.64 In the present study,
expression of Col1a1, collagen density, and AKT phos-
phorylation were all markedly decreased in wound sites of
Foxo1þ/ mice 7 days after injury. We also found that
knockdown of FOXO1 in PKs signiﬁcantly enhanced the
ERK pathway after mFGF2 application. Local administra-
tion of FGF2 to the human incisional wound reduces scar-
ring.65 We speculate that the attenuation of FOXO1 in
wound ﬁbroblasts contributes to reduced scarring through
the FGF2 pathway. We are presently exploring how FOXO1
regulates scarring at wound sites in the presence of several
wound growth factors, including FGF2. Further studies
using other models, such as keratinocyte-speciﬁc Foxo1/
mice,21 are required to better elucidate the pathophysio-
logical signiﬁcance of FOXO1 function in skin ﬁbrosis.
In patients, the most extreme scarring phenotype is that of
keloid scarring, where scar tissue spills out from the initial
site of tissue damage. Our keloid studies showed FOXO1 is
highly expressed in ﬁbroblasts and inﬂammatory cells at the
margin of a keloid compared with those ﬁbroblasts in
mature keloid sites, and that FOXO1 expression level was
altered between African Americans and Japanese. These
results indicate that FOXO1 may regulate the expression of
collagen and, thus, its expression level may play a key role
in scarring and keloids. Current investigations are focusing2477
Mori et alon the implications of FOXO1 polymorphisms on ﬁbrotic
diseases. Disequilibrium of FOXO1 is believed to affect
human longevity66,67 and, thus, polymorphism of FOXO1
may also affect homeostasis at the cellular and individual
level as well. Therefore, a functional analysis of FOXO1
polymorphisms may further elucidate the differences in
keloid morbidity and repair phenotypes by age and race.
Determining how the FOXO1 signaling pathway regulates
keloid progression for the homeostatic maintenance between
proliferation and differentiation will thus be important to
explore in future studies.
In conclusion, the age-related gene FOXO1 plays a cen-
tral role for tissue repair and remodeling. It may be
considered a potential therapeutic target for enhancing tissue
repair and remodeling as well as for dampening inﬂamma-
tory diseases and ﬁbrosis.
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